Veracyte Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company was founded in 2006 and is based in San Francisco, California.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Veracyte, are expected to be $180.0 million. All of the shares are being offered by the Company. The offering is
Veracyte, Inc. (VCYT) Q2 2020 Earnings Conference Call July 30, 2020 16:30 ET Company Participants Tracy Morris - Vice President, Corporate Communications and Investor Relations Bonnie Anderson - Chairman and Chief Executive Officer Keith Kennedy - Chief Operating Officer and Chief Financial Officer John Hanna - Chief Commercial Officer Conference...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. Veracyte intends to use the net p